L. Rodrigues

Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.

D. Sage, R. Pagliarini, Pascal D. Fortin, 2017, Structure.

Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.

M. Loda, M. Lucia, J. Costello, 2015, Cancer research.

Supplemental Information Allosteric Mutant IDH 1 Inhibitors Reveal Mechanisms for IDH 1 Mutant and Isoform Selectivity

Pascal D. Fortin, D. Baird, H. Yin, 2017 .

MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1

M. Lucia, J. Costello, R. Nolley, 2021, Molecular Cancer Research.

Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer

Leah Rider, Adela Cimic, Isabel R Schlaepfer, 2014, Molecular Cancer Therapeutics.

Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells

A. Odermatt, G. Kerr, U. Naumann, 2021, Molecular therapy. Methods & clinical development.

MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells

L. Miller, J. Chou, S. Cramer, 2020, Molecular therapy oncolytics.

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia

F. Mapa, Peter Aspesi, A. Kauffmann, 2021, bioRxiv.